GJIA
NVCR icon

Glass Jacobson Investment Advisors’s NovoCure NVCR Stock Holding History

Glass Jacobson Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200
Closed -$2.99K – 773
2023
Q4 		$2.99K Hold
200
– – ﹤0.01% 628
2023
Q3 		$3.23K Hold
200
– – ﹤0.01% 595
2023
Q2 		$8.3K Buy
+200
New +$12.4K ﹤0.01% 527
2022
Q4 		$14.7K Buy
+200
New +$15K 0.01% 471

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glass Jacobson Investment Advisors's NVCR Position: Q1 2024 in Review

Glass Jacobson Investment Advisors sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 200 shares — an estimated $2.99K sold.

Glass Jacobson Investment Advisors first reported a position in NVCR in Q4 2022 and held it in 4 quarters. The position peaked at $14.7K in Q4 2022. 238 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

  • Glass Jacobson Investment Advisors reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
  • Glass Jacobson Investment Advisors sold 200 NovoCure shares in Q1 2024, an estimated $2.99K.
  • Glass Jacobson Investment Advisors first reported a position in NovoCure in Q4 2022 and held it in 4 quarters.
  • Glass Jacobson Investment Advisors's NovoCure position peaked at $14.7K in Q4 2022.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Glass Jacobson Investment Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.